Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus RVD versus RVD alone for first relapsed multiple myeloma
ChiCTR2000033109Phase 3Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of decitabine, lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Objective response rate and Progression-free survival. Started May 2020; status: recruiting.
02
Drugs
decitabinelenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000033109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033109.